64 results
8-K
EX-99.3
MDXG
Mimedx Group Inc
30 Apr 24
MIMEDX Announces First Quarter 2024 Operating and Financial
4:10pm
with a Management Leads holistic multispecialty team approach that incorporates innovative 2 to Poor Outcomes treatments and adherence to treatment parameters … Portfolio Innovative Offering for Surgical Market Emerging Xenograft Portfolio Announced exclusive manufacturing and supply agreement with Regenity
8-K
EX-99
MDXG
Mimedx Group Inc
4 Mar 24
MIMEDX Announces Appointment of Two New Independent Directors
8:11am
together to unlock the full potential MIMEDX has to offer the industry as a leader in innovative Wound Care and Surgical therapeutics.”
Joseph H. Capper
8-K
EX-99.2
ebrwf0uplr8v 9v
13 Nov 23
MIMEDX to Participate in Upcoming Investor Conferences
8:14am
8-K
EX-99.1
whi1i8ux7p
2 Aug 22
MIMEDX Announces Second Quarter 2022 Operating and Financial Results
4:09pm
8-K
EX-99.1
xso3u 858k
30 Jun 22
Regulation FD Disclosure
4:38pm
DEFA14A
6yhh64ves52y
9 May 22
Additional proxy soliciting materials
4:48pm
8-K
EX-99.3
8vh9j20 fhcsq6
7 Dec 21
Regulation FD Disclosure
12:45pm
8-K
EX-99.2
49a0d7bw78l
7 Dec 21
Regulation FD Disclosure
12:45pm
DFAN14A
90sk 2lgw37
4 May 21
Additional proxy materials by non-management
2:59pm
DEFA14A
0f471yndjwpdzxwipqh3
3 May 21
Additional proxy soliciting materials
8:36am
DEFA14A
7lq3r wtfrlv0axnog
3 May 21
Additional proxy soliciting materials
8:28am